4 results match your criteria: "Gastroenterology and Hepatology University of Iowa Hospitals and Clinics Iowa City Iowa USA.[Affiliation]"
Article Synopsis
- Patients who have undergone solid organ transplants are at higher risk for severe COVID-19 due to immunosuppressive therapy, necessitating better vaccination and treatment strategies.
- A study assessed the outcomes of liver and kidney transplant recipients diagnosed with COVID-19, focusing on factors like vaccine doses and monoclonal antibody (mAb) therapy.
- Results showed that while some vaccine doses had no impact, liver transplant patients on mycophenolate had significantly higher mortality rates, and those receiving mAb therapy had lower hospitalization rates, highlighting the need for tailored treatment approaches in this vulnerable group.*
Readmission Rate, Predictors, Outcomes, and Burden of Readmission of Hepatorenal Syndrome in the United States: A Nationwide Analysis.
JGH Open
November 2024
Department of Internal Medicine, Gastroenterology and Hepatology University of Iowa Hospitals and Clinics Iowa City Iowa USA.
Background: Nationwide US data on readmission rates for patients with cirrhosis admitted with hepatorenal syndrome (HRS) is lacking. We reviewed 30-day readmission rates after HRS-related hospitalizations, the associated predictors of readmissions, and their impact on resource utilization and mortality in the United States.
Methods: We identified all adults admitted with HRS between 2016 and 2019 using the Nationwide Readmission database of the Agency for Healthcare Research and Quality's Healthcare Cost and Utilization Project.
In post-liver transplant patients, esophagitis presents a diagnostic and management challenge due to the potential for opportunistic infections. This case describes a 59-year-old female with primary sclerosing cholangitis who underwent orthotopic liver transplantation six years prior. She presented with dysphagia, and her medical history included immunosuppression with prednisone, tacrolimus, and mycophenolate and a history of achalasia treated with esophageal peroral endoscopic myotomy.
View Article and Find Full Text PDFBackground And Aim: Previous studies conducted at single centers have suggested that patients with cirrhosis are at a greater risk for worse outcomes with COVID-19. However, there is limited data on a national level in the United States. We aimed to study hospital-related outcomes and identify the predictors of poor outcomes in patients with cirrhosis and concurrent COVID-19.
View Article and Find Full Text PDF